ArticleInfectious diseases and therapy2026
Cost-Effectiveness of Routine Infant Meningococcal B Vaccination in the Netherlands.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInvasive meningococcal disease (IMD) is a severe infectious disease that can cause mortality and debilitating sequelae. IMD is typically vaccine-preventable. In the Netherlands, meningococcal serogroup B (MenB) causes almost all IMD cases. The objective of this study was to assess the cost-effectiveness of routine infant MenB vaccination in the Netherlands, using the latest incidence data, real-world evidence and vaccine data.
methodsWe used the dynamic transmission cost-effectiveness (DyCE) model to compare routine infant vaccination with three doses of the four-component meningococcal B vaccine (4CMenB) versus no MenB vaccination, from a societal perspective. The model followed 100 cohorts over lifetime, was updated with the most recent Dutch epidemiological evidence, and was adapted in accordance with the latest Dutch health economic guidelines. Additionally, IMD incidence was varied in scenario analyses to model the unpredictable incidence of MenB IMD and potential outbreaks of this disease.
resultsOver lifetime, 2367 MenB IMD cases, 1077 long-term sequelae cases and 116 deaths were prevented with 4CMenB vaccination in the base case. 4CMenB vaccination saved 14,703 quality-adjusted life years (QALYs), predominantly by preventing long-term sequelae (45.5%) and deaths (52.2%). The incremental cost-effectiveness ratio (ICER) was €99,752 per QALY gained in the base case and decreased below the willingness-to-pay threshold of 80,000 if the IMD incidence increased by 24%, or if the vaccine acquisition costs decreased by 22% (from €78.5 to €61.45). The ICER was most sensitive to variations in vaccine effectiveness, the incidence of MenB IMD and vaccine acquisition costs.
conclusionsIn the Netherlands, 4CMenB vaccination is likely to be cost-effective if MenB incidence increases by 24%. This comprehensive analysis provides decision-makers with new and updated information on the cost-effectiveness of infant vaccination with 4CMenB in the Netherlands.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.